// App-Quantinova.ai

99 : Preliminary analysis of a U.S. phase II study of the safety and tolerability of proxalutamide (GT0918) in subjects with mCRPC who had progressed on either abiraterone (Abi) or enzalutamide (Enza).

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Richard Levin

  • Arash Rezazadeh

  • Chandler H. Park

  • Britt Haley Bolemon

  • Nashat Y. Gabrail

  • Zulfiqar A. Malik

  • Luke T. Nordquist

  • Ashley Ross

  • Phoebe Zhang

  • Karl Zhou

Medical Centers

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Chesapeake Urology Research Associates, Baltimore, MD

  • UC Irvine Health, Orange, CA

  • Indiana University, Indianapolis, IN

  • Greenville Health System, Greenville, SC

  • Gabrail Cancer Center, Canton, OH

  • Suburban Medcl Plz II, Louisville, KY

  • GU Research Network, LLC, Omaha, NE

  • Johns Hopkins Medicine, Baltimore, MD

  • Zinfandel Pharmaceuticals Inc., Chapel Hill, NC

  • Kintor Pharmaceuticals, Inc., Chape Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Docetaxel

  • GT0918

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02826772

  • NCT03899467

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved